SEC Form 4 · accession 0001735276-18-000072
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Mason
Officer — VP, Finance and Treasurer
Period of report
Sep 27, 2018
Accepted (ET)
Sep 28, 2018 · 4:55 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance Stock Option 2015 (right to buy) | $88.95 | Sep 27, 2018 | A | 1,800 | A | Sep 27, 2018 | Dec 18, 2025 | Common Stock | 1,800 | 5,400 | D |
| Performance Stock Option 2016 (right to buy) | $42.22 | Sep 27, 2018 | A | 1,387 | A | Sep 27, 2018 | Dec 20, 2026 | Common Stock | 1,387 | 2,775 | D |
Explanation of responses
- F1On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development and regulatory events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the third performance criterion had been met and the option vested as to one-quarter of the shares.
- F2On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option will vest upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. Effective September 27, 2018, the compensation committee of the Company determined the second performance criterion had been met and the option vested as to one-quarter of the shares.